ArticleConsortium psychiatricum2026
Chatbot Remote Monitoring System in Patients with Schizophrenia: A Pilot Study of User Experience.
Article in Consortium psychiatricum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemote monitoring of remission status in patients with schizophrenia spectrum disorders (SSDs) is a promising approach for the early detection of mental disorder relapses. However, there are currently no validated digital tools available for this purpose in Russia. An important prerequisite for the development of such tools is assessing user experience, as it largely determines patient adherence to self-monitoring.
aimTo evaluate the user experience associated with chatbot-based remote monitoring of remission in patients with schizophrenia spectrum disorders.
methodsOver a 9-day period, patients completed a digital diary using a chatbot (a total of five morning and five evening sessions). To reduce respondent burden, the diary questions were divided into two blocks. The morning session included a questionnaire for the self-assessment of psychotic and affective symptoms, including 12 items from the Positive and Negative Syndrome Scale (PANSS), 2 items from the Calgary Depression Scale for Schizophrenia (CDSS), the Spiegel Sleep Questionnaire (SSQ), and the 4-item Morisky-Green-Levine Medication Adherence Questionnaire (MGL-4). The evening session included the short-form of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) and the patient version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). After the self-monitoring period had been completed, participants evaluated their experience interacting with the technology using a 21-item questionnaire.
resultsThe study included 15 patients with SSDs. Most participants (80%) completed more than half of the diary sessions. Participants reported high satisfaction with the chatbot functionality and good acceptability of the technology overall. Among the limitations of the remote monitoring system, participants mentioned the large number of questions and the lack of personalized notifications.
conclusionPatients with SSDs responded positively to the use of a chatbot for remote monitoring of remission. Further improvements should include streamlined patient interactions and personalized features such as medication reminders and visual symptom tracking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.